Pfizer's Post-Pandemic Transformation: AI-Driven Cost Reduction and Efficiency Improvement, Monthly Weight Loss Drug Data Ignites Future Expectations

Wallstreetcn

2026.02.03 19:15

Financial Performance: Revenue of $62.6 billion in 2025 (down 2% year-on-year), mainly affected by a significant decline in demand for COVID-19 products. However, non-COVID business revenue grew by 6%, demonstrating the resilience of core operations.
Breakthrough in Weight Loss Drug: Positive data from the VESPER-3 Phase II clinical trial disclosed. Its ultra-long-acting GLP-1 agonist (3944) achieved once-monthly injections, with a weight loss effect of 10%-12.3% over 28 weeks (excluding placebo effects), and the high-dose group is projected to lose 16%. The company plans to initiate 10 Phase III clinical studies in 2026, aiming for approval in 2028.
AI Strategy: Pfizer will deploy 1,200 GPUs internally within two years, fully embedding AI into research, production, and marketing processes. The $7.2 billion cost savings target for 2025 is primarily leveraged by AI-driven efficiency improvements.
Expansion in Oncology: Strong performance of ADC drug PADCEV acquired from Seagen, expanding the target patient population for bladder cancer by approximately 22,500 through combination therapy, becoming an important growth point post-2028.
Capital and Guidance: Maintains revenue guidance for 2026 ($59.5 billion - $62.5 billion). Despite facing patent expiration pressures, the company commits to maintaining and growing quarterly dividends (having distributed $9.8 billion in 2025).
Risk Points: $4.4 billion asset impairment due to adjustments in the R&D pipeline in the fourth quarter; and due to large-scale acquisitions and patent expirations, the debt ratio is expected to remain around 2.7 times in the coming years